REFERENCES
1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88.
2. Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019;71:104-14.
3. Jutric Z, Johnston WC, Hoen HM, et al. Impact of lymph node status in patients with intrahepatic cholangiocarcinoma treated by major hepatectomy: a review of the National Cancer Database. HPB 2016;18:79-87.
4. Cadamuro M, Romanzi A, Guido M, et al. Translational value of tumor-associated lymphangiogenesis in cholangiocarcinoma. J Pers Med 2022;12:1086.
5. Kodali S, Saharia A, Ghobrial RM. Liver transplantation and intrahepatic cholangiocarcinoma: time to go forward again? Curr Opin Organ Transplant 2022;27:320-8.
6. Aliseda D, Martí-Cruchaga P, Zozaya G, et al. Liver resection and transplantation following yttrium-90 radioembolization for primary malignant liver tumors: a 15-year single-center experience. Cancers 2023;15:733.
7. Brivio S, Cadamuro M, Strazzabosco M, Fabris L. Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness. World J Hepatol 2017;9:455-68.
8. Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology 2014;59:2397-402.
9. Carpino G, Overi D, Melandro F, et al. Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure. Clin Proteomics 2019;16:37.
10. Cadamuro M, Brivio S, Mertens J, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol 2019;70:700-9.
11. Carpino G, Cardinale V, Di Giamberardino A, et al. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. J Hepatol 2021;75:1377-86.
12. Cadamuro M, Fabris L, Zhang X, Strazzabosco M. Tumor microenvironment and immunology of cholangiocarcinoma. HR 2022;8:11.
13. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011;9:44-54.
14. Okabe H, Beppu T, Hayashi H, et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16:2555-64.
15. Dranoff JA, Wells RG. Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology 2010;51:1438-44.
16. Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011;19:257-72.
17. Cadamuro M, Nardo G, Indraccolo S, et al. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 2013;58:1042-53.
18. da Cunha BR, Domingos C, Stefanini ACB, et al. Cellular interactions in the tumor microenvironment: the role of secretome. J Cancer 2019;10:4574-87.
19. Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int 2019;39 Suppl 1:63-78.
20. Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013;58:1992-2000.
21. Sirica AE, Almenara JA, Li C. Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications. Exp Mol Pathol 2014;97:515-24.
22. Sirica AE. Matricellular proteins in intrahepatic cholangiocarcinoma. hepatobiliary cancers: translational advances and molecular medicine. Elsevier; 2022. pp. 249-81.
23. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196:395-406.
24. Mohan V, Das A, Sagi I. Emerging roles of ECM remodeling processes in cancer. Semin Cancer Biol 2020;62:192-200.
25. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci 2010;123:4195-200.
26. Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev 2016;97:4-27.
28. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 2014;15:786-801.
29. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139:891-906.
30. Maller O, Drain AP, Barrett AS, et al. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat Mater 2021;20:548-59.
31. Al-Zuhair AG, Al-Adnani MS, Al-Bader AA, Francis IM. Expression of connective tissue stromal elements in human cholangiocarcinomas. an immunohistochemical and ultrastructural study. J Submicrosc Cytol 1987;19:321-7.
33. Lai KK, Shang S, Lohia N, et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 2011;7:e1002147.
34. Gelse K, Pöschl E, Aigner T. Collagens--structure, function, and biosynthesis. Adv Drug Deliv Rev 2003;55:1531-46.
35. Exposito JY, Valcourt U, Cluzel C, Lethias C. The fibrillar collagen family. Int J Mol Sci 2010;11:407-26.
36. Okamura N, Yoshida M, Shibuya A, et al. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int 2005;55:724-31.
37. Linsenmayer TF, Gibney E, Igoe F, et al. Type V collagen: molecular structure and fibrillar organization of the chicken alpha 1(V) NH2-terminal domain, a putative regulator of corneal fibrillogenesis. J Cell Biol 1993;121:1181-9.
38. Von Der Mark K. Structure, biosynthesis and gene regulation of collagens in cartilage and bone. dynamics of bone and cartilage metabolism. Elsevier; 2006. pp. 3-40.
39. Yu X, Zou Y, Li Q, et al. Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro. Tumour Biol 2014;35:3103-12.
40. Mak KM, Mei R. Basement membrane type IV collagen and laminin: an overview of their biology and value as fibrosis biomarkers of liver disease. Anat Rec 2017;300:1371-90.
41. Terada T, Nakanuma Y. Expression of tenascin, type IV collagen and laminin during human intrahepatic bile duct development and in intrahepatic cholangiocarcinoma. Histopathology 1994;25:143-50.
42. Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview. Gene Expr 2018;18:31-50.
44. Keene DR, Engvall E, Glanville RW. Ultrastructure of type VI collagen in human skin and cartilage suggests an anchoring function for this filamentous network. J Cell Biol 1988;107:1995-2006.
45. Takahara T, Sollberg S, Muona P, Uitto J. Type VI collagen gene expression in experimental liver fibrosis: quantitation and spatial distribution of mRNAs, and immunodetection of the protein. Liver 1995;15:78-86.
46. Baiocchini A, Montaldo C, Conigliaro A, et al. Extracellular matrix molecular remodeling in human liver fibrosis evolution. PLoS One 2016;11:e0151736.
47. Chen P, Cescon M, Bonaldo P. Collagen VI in cancer and its biological mechanisms. Trends Mol Med 2013;19:410-7.
48. Trueb B, Odermatt BF. Loss of type VI collagen in experimental and most spontaneous human fibrosarcomas. Int J Cancer 2000;86:331-6.
49. Izzi V, Heljasvaara R, Heikkinen A, Karppinen SM, Koivunen J, Pihlajaniemi T. Exploring the roles of MACIT and multiplexin collagens in stem cells and cancer. Semin Cancer Biol 2020;62:134-48.
50. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin’s antiangiogenic signaling network. Mol Cell 2004;13:649-63.
51. Musso O, Theret N, Heljasvaara R, et al. Tumor hepatocytes and basement membrane-Producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers. Hepatology 2001;33:868-76.
52. Saarela J, Ylikärppä R, Rehn M, Purmonen S, Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 1998;16:319-28.
53. Cox TR, Bird D, Baker AM, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013;73:1721-32.
54. Lin HY, Li CJ, Yang YL, et al. Roles of lysyl oxidase family members in the tumor microenvironment and progression of liver cancer. Int J Mol Sci 2020;21:9751.
55. Bergeat D, Fautrel A, Turlin B, et al. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma. J Surg Res 2016;203:441-50.
56. Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66.
57. Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 1996;23:1341-4.
58. Jones CE, Sharick JT, Colbert SE, et al. Pten regulates collagen fibrillogenesis by fibroblasts through SPARC. PLoS One 2021;16:e0245653.
59. Deng S, Zhang L, Li J, Jin Y, Wang J. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells. Tissue Cell 2022;76:101756.
60. Sonongbua J, Siritungyong S, Thongchot S, et al. Periostin induces epithelial-to-mesenchymal transition via the integrin α5β1/TWIST-2 axis in cholangiocarcinoma. Oncol Rep 2020;43:1147-58.
61. Provenzano PP, Eliceiri KW, Campbell JM, et al. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006;4:38.
62. Ray A, Slama ZM, Morford RK, Madden SA, Provenzano PP. Enhanced directional migration of cancer stem cells in 3D aligned collagen matrices. Biophys J 2017;112:1023-36.
63. Huang Y, Zhuang Z. Second harmonic microscopic imaging and spectroscopic characterization in prostate pathological tissue. Scanning 2014;36:334-7.
64. Drifka CR, Loeffler AG, Mathewson K, et al. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget 2016;7:76197-213.
65. Deng B, Zhao Z, Kong W, Han C, Shen X, Zhou C. Biological role of matrix stiffness in tumor growth and treatment. J Transl Med 2022;20:540.
66. Keikhosravi A, Shribak M, Conklin MW, et al. Real-time polarization microscopy of fibrillar collagen in histopathology. Sci Rep 2021;11:19063.
67. Shi R, Zhang Z, Zhu A, et al. Targeting type I collagen for cancer treatment. Int J Cancer 2022;151:665-83.
68. Baldari S, Di Modugno F, Nisticò P, Toietta G. Strategies for efficient targeting of tumor collagen for cancer therapy. cancers 2022;14:4706.
69. Liang H, Li X, Wang B, et al. A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix. Sci Rep 2016;6:18205.
70. Momin N, Mehta NK, Bennett NR, et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med 2019:11.
71. Smithen DA, Leung LMH, Challinor M, et al. 2-Aminomethylene-5-sulfonylthiazole inhibitors of lysyl oxidase (LOX) and LOXL2 show significant efficacy in delaying tumor growth. J Med Chem 2020;63:2308-24.
72. Liu YL, Bager CL, Willumsen N, et al. Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. NPJ Breast Cancer 2021;7:108.
73. Peng T, Deng X, Tian F, et al. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma. Int J Oncol 2019;55:657-70.
74. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-70.
75. Cortes E, Lachowski D, Rice A, et al. Tamoxifen mechanically deactivates hepatic stellate cells via the G protein-coupled estrogen receptor. Oncogene 2019;38:2910-22.
76. Nicolas-Boluda A, Vaquero J, Vimeux L, et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife 2021:10.
77. Ortona E, Maselli A, Delunardo F, Colasanti T, Giovannetti A, Pierdominici M. Relationship between redox status and cell fate in immunity and autoimmunity. Antioxid Redox Signal 2014;21:103-22.
78. Su B, Zhao W, Shi B, et al. Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7. Mol Cancer 2014;13:206.
